TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Genedrive ( (GB:GDR) ) has provided an update.
Genedrive plc has announced the agreement of terms for a potential £1 million shareholder loan from David Nugent, a significant shareholder. The loan, which will be secured against the company’s assets, is intended to improve Genedrive’s working capital position, allowing it to continue its operations and strategic growth in the pharmacogenetic testing market. The loan will be provided in two tranches, with the first being interest-free and the second incurring a one-off charge, highlighting the financial support and confidence from stakeholders in Genedrive’s future prospects.
The most recent analyst rating on (GB:GDR) stock is a Hold with a £1.50 price target. To see the full list of analyst forecasts on Genedrive stock, see the GB:GDR Stock Forecast page.
Spark’s Take on GB:GDR Stock
According to Spark, TipRanks’ AI Analyst, GB:GDR is a Neutral.
Genedrive is navigating profitability challenges despite strong revenue growth and a solid balance sheet. Technical analysis indicates bearish momentum, while valuation metrics are unappealing due to lack of profitability. However, recent corporate developments are promising, potentially enhancing market positioning and future prospects.
To see Spark’s full report on GB:GDR stock, click here.
More about Genedrive
Genedrive plc is a UK-based pharmacogenetic testing company that develops and commercializes a low-cost, rapid, and versatile point-of-need pharmacogenetic platform. This platform aids clinicians in making informed decisions about medication and dosage, particularly in emergency healthcare settings. The company’s flagship products, the Genedrive® MT-RNR1 ID Kit and the Genedrive® CYP2C19 ID Kit, are designed for quick genetic variant diagnosis and have been recommended for use by the UK NHS.
Average Trading Volume: 56,685,463
Technical Sentiment Signal: Sell
Current Market Cap: £8.24M
Find detailed analytics on GDR stock on TipRanks’ Stock Analysis page.